SPRY
Price:
$17.9
Market Cap:
$1.76B
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
Industry
Biotechnology
IPO Date
2020-12-04
Stock Exchange
NASDAQ
Ticker
SPRY
According to ARS Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 11.00. This represents a change of -37.71% compared to the average of 17.66 of the last 4 quarters.
The mean historical Current Ratio of ARS Pharmaceuticals, Inc. over the last ten years is 25.35. The current 11.00 Current Ratio has changed 4.24% with respect to the historical average. Over the past ten years (40 quarters), SPRY's Current Ratio was at its highest in in the December 2023 quarter at 96.85. The Current Ratio was at its lowest in in the March 2020 quarter at 0.
Average
25.35
Median
7.42
Minimum
0.59
Maximum
96.92
Discovering the peaks and valleys of ARS Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 587.67%
Maximum Annual Current Ratio = 96.92
Minimum Annual Increase = -85.46%
Minimum Annual Current Ratio = 0.59
Year | Current Ratio | Change |
---|---|---|
2024 | 14.26 | -85.28% |
2023 | 96.92 | 89.99% |
2022 | 51.01 | 587.67% |
2021 | 7.42 | 130.84% |
2020 | 3.21 | 447.14% |
2019 | 0.59 | -85.46% |
The current Current Ratio of ARS Pharmaceuticals, Inc. (SPRY) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
54.06
5-year avg
34.56
10-year avg
25.35
ARS Pharmaceuticals, Inc.’s Current Ratio is greater than TScan Therapeutics, Inc. (8.55), greater than Dermata Therapeutics, Inc. (6.97), greater than IN8bio, Inc. (4.30), greater than Zura Bio Limited (8.14), greater than Ocean Biomedical, Inc. (0.06), less than Elevation Oncology, Inc. (19.40),
Company | Current Ratio | Market cap |
---|---|---|
8.55 | $104.13M | |
6.97 | $4.14M | |
4.30 | $8.58M | |
8.14 | $83.53M | |
0.06 | $4.15M | |
19.40 | $22.63M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like ARS Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like ARS Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Current Ratio?
How can you use the Current Ratio?
What is ARS Pharmaceuticals, Inc.'s Current Ratio?
How is the Current Ratio calculated for ARS Pharmaceuticals, Inc. (SPRY)?
What is the highest Current Ratio for ARS Pharmaceuticals, Inc. (SPRY)?
What is the 3-year average Current Ratio for ARS Pharmaceuticals, Inc. (SPRY)?
What is the 5-year average Current Ratio for ARS Pharmaceuticals, Inc. (SPRY)?
How does the current Current Ratio for ARS Pharmaceuticals, Inc. (SPRY) compare to its historical average?